Advanced RCC: nivolumab shows benefit even after progression

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • 13% of patients with advanced renal cell carcinoma (aRCC) treated beyond progression (TBP) with nivolumab (Opdivo) experiencing ≥30% further decrease in tumor burden.
  • Tumor burden reduction was observed in patients who initially responded and then progressed, and patients with stable disease or progressive disease as best overall response. 
  • Acceptable safety profile was maintained.

Why this matters

  • In November 2015, nivolumab became the first immune checkpoint inhibitor approved for aRCC. 
  • Immunotherapies are associated with tumor flare, with increased tumor burden or new lesions preceding clinical responses.
  • This may be mistaken for disease progression and lead to discontinuation.

Study design

  • 316 patients with aRCC who progressed on nivolumab were included.
  • Funding: Bristol-Myers Squibb ...